Stock LPCN LIPOCINE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Lipocine Inc.

Equities

LPCN

US53630X2036

Real-time Estimate Cboe BZX
Other stock markets
 10:50:56 2024-05-03 am EDT 		5-day change 1st Jan Change
4.97 USD +5.74% Intraday chart for Lipocine Inc. +4.79% +80.20%
May. 01 Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 CI
Apr. 12 Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
PR
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
AQ
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
PR
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
PR
Lipocine : Announces First Cohort Dosed in Pivotal Study of LPCN 1154 - Form 8-K
PU
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
AQ
Lipocine : Announces Financial Results for the Full Year Ended December 31, 2023 - Form 8-K
PU
Lipocine to Present at 36th Annual Roth Conference
PR
Lipocine : to Present at 36th Annual Roth Conference - Form 8-K
PU
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
PR
Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
PR
Lipocine and Verity Pharma Enter into License Agreement for TLANDO Franchise in the U.S. and Canada
AQ
Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada
PR
Lipocine to Present at Biotech Showcase 2024
PR
Lipocine: Q3 Earnings Snapshot
AQ
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023
PR
Lipocine to Present Clinical Data on LPCN 1148 at the Liver Meeting 2023
AQ
Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression
PR
Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference
PR
Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LPCN Stock
  4. News Lipocine Inc.
  5. Press Releases